Skip to main content
Top
Published in: Journal of Hematology & Oncology 1/2022

Open Access 01-12-2022 | Colonoscopy | Correspondence

FIT-based risk-stratification model effectively screens colorectal neoplasia and early-onset colorectal cancer in Chinese population: a nationwide multicenter prospective study

Authors: Shengbing Zhao, Shuling Wang, Peng Pan, Tian Xia, Rundong Wang, Quancai Cai, Xin Chang, Fan Yang, Lun Gu, Zixuan He, Jiayi Wu, Qianqian Meng, Tongchang Wang, Qiwen Fang, Xiaomei Mou, Honggang Yu, Jinghua Zheng, Cheng Bai, Yingbin Zou, Dongfeng Chen, Xiaoping Zou, Xu Ren, Leiming Xu, Ping Yao, Guangsu Xiong, Xu Shu, Tong Dang, Li Zhang, Wen Wang, Shengchao Kang, Hongfei Cao, Aixia Gong, Jun Li, Heng Zhang, Yiqi Du, Zhaoshen Li, Yu Bai, Gastrointestinal Early Cancer Prevention & Treatment Alliance of China (GECA)

Published in: Journal of Hematology & Oncology | Issue 1/2022

Login to get access

Abstract

No fully validated risk-stratification strategies have been established in China where colonoscopies resources are limited. We aimed to develop and validate a fecal immunochemical test (FIT)-based risk-stratification model for colorectal neoplasia (CN); 10,164 individuals were recruited from 175 centers nationwide and were randomly allocated to the derivation (n = 6776) or validation cohort (n = 3388). Multivariate logistic analyses were performed to develop the National Colorectal Polyp Care (NCPC) score, which formed the risk-stratification model along with FIT. The NCPC score was developed from eight independent predicting factors and divided into three levels: low risk (LR 0–14), intermediate risk (IR 15–17), and high risk (HR 18–28). Individuals with IR or HR of NCPC score or FIT+ were classified as increased-risk individuals in the risk-stratification model and were recommended for colonoscopy. The IR/HR of NCPC score showed a higher prevalence of CNs (21.8%/32.8% vs. 11.0%, P < 0.001) and ACNs (4.3%/9.2% vs. 2.0%, P < 0.001) than LR, which was also confirmed in the validation cohort. Similar relative risks and predictive performances were demonstrated between non-specific gastrointestinal symptoms (NSGS) and asymptomatic cohort. The risk-stratification model identified 73.5% CN, 82.6% ACN, and 93.6% CRC when guiding 52.7% individuals to receive colonoscopy and identified 55.8% early-onset ACNs and 72.7% early-onset CRCs with only 25.6% young individuals receiving colonoscopy. The risk-stratification model showed a good risk-stratification ability for CN and early-onset CRCs in Chinese population, including individuals with NSGS and young age.
Appendix
Available only for authorised users
Literature
Metadata
Title
FIT-based risk-stratification model effectively screens colorectal neoplasia and early-onset colorectal cancer in Chinese population: a nationwide multicenter prospective study
Authors
Shengbing Zhao
Shuling Wang
Peng Pan
Tian Xia
Rundong Wang
Quancai Cai
Xin Chang
Fan Yang
Lun Gu
Zixuan He
Jiayi Wu
Qianqian Meng
Tongchang Wang
Qiwen Fang
Xiaomei Mou
Honggang Yu
Jinghua Zheng
Cheng Bai
Yingbin Zou
Dongfeng Chen
Xiaoping Zou
Xu Ren
Leiming Xu
Ping Yao
Guangsu Xiong
Xu Shu
Tong Dang
Li Zhang
Wen Wang
Shengchao Kang
Hongfei Cao
Aixia Gong
Jun Li
Heng Zhang
Yiqi Du
Zhaoshen Li
Yu Bai
Gastrointestinal Early Cancer Prevention & Treatment Alliance of China (GECA)
Publication date
01-12-2022
Publisher
BioMed Central
Published in
Journal of Hematology & Oncology / Issue 1/2022
Electronic ISSN: 1756-8722
DOI
https://doi.org/10.1186/s13045-022-01378-1

Other articles of this Issue 1/2022

Journal of Hematology & Oncology 1/2022 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine